Given a paragraph, generate a claim that is supported by the given paragraph. 1) The claim must contain information from within the paragraph. 2) A sentence within the paragraph can be used as a claim. 3) The claim should not have contradictions within the paragraph. 4) The claim should be at most one sentence long.

Input: Consider Input: Four times as many black people are being detained as white people. If you're black, you're about four times as likely to be detained than if you're white. Overall, more white people are detained, since they make up a larger portion of the population. The number of people detained under the Mental Health Act has increased by 47% in ten years. Correct in England between 2005/06 and 2015/16. Claim 1 of 3

Output: People from black and minority ethnic populations are most affected by detentions under the Mental Health Act.


Input: Consider Input: The Hall of Fame rocker, who has been an advocate for teen cancer patients for nearly three decades, visited with children, young adults and their families at Rainbow Babies Hospital on Monday. The Who’s front man toured the Angie Fowler Adolescent & Young Adult Cancer Institute, which was founded in 2012 to better serve young patients while they undergo cancer treatments and following their release. “Teenagers for so long have been overlooked,” said the 73-year-old, still on the road with longtime bandmate Pete Townshend. “Not nearly enough has been done for them.” For years, teenage cancer patients were hospitalized on pediatric floors or placed with older patients. After consulting with doctors researching treatments and recovery, Daltrey understood the need for teens to have a place of their own, where they could recover in surroundings more suited to their interests and maturity level. “The light went on in my head with this one,” said Daltrey, who first got involved with the Teenage Cancer Trust in 1989. “I was in the Who when I was 18 years old and without the support of this age group — adolescents and young adults — our business wouldn’t be there. The music business is built mostly with this age group. It’s an easy way for me to say, ‘Thank you.’” During his visit, Daltrey, whose iconic voice helped make Who songs such as “My Generation,” ″Behind Blue Eyes” and “Won’t Get Fooled Again” anthems for generations of fans, spent time with young cancer patients who have benefited from their time in facilities like the one at Rainbow Babies Hospital. Daltrey quickly connected with several of the teens, who eagerly shared stories of being diagnosed and lengthy hospital stays. He had a warm word, hug or handshake for each of them and was happy to pose for photos. For Adam Kirk, Daltrey’s visit was a chance to meet a rock hero. The 40-year-old’s daughter, Sawyer, has been fighting leukemia for months and Daltrey’s face lit up when he saw the 1½-year-old being carried toward him. Kirk came prepared for his meeting, getting Daltrey to sign a well-worn copy of “Who’s Next,” regarded as the band’s signature album. As he made his way around an outdoor, rooftop garden, Daltrey was approached by another dad who wanted to show his appreciation for the singer’s charitable work. Tyson Stiles presented Daltrey with a musical gift. While his son, Ryver, spent nearly 300 days in the hospital after being born prematurely, Stiles recorded a short album that included songs he wrote about his son’s ordeal. “I wanted you to have a copy,” Stiles said. “Is it any good?” Daltrey asked. “No, it’s terrible,” Stiles quipped as both men laughed. Later, Daltrey donated a guitar signed by him and Townshend that will be permanently displayed in the Fowler Institute’s in-patient unit. Daltrey also shared memories of his previous visits to Cleveland. He and the Who first came to town in 1967. “It’s a lot different than it used to be,” he said. “It was the dirtiest place I’d ever been to in my life. Everything was covered in soot. But Cleveland audiences were some of the best we ever played for.”

Output: The Who’s Roger Daltrey visits teenage cancer patients.


Input: Consider Input: The release makes no mention of the cost of the drug in question, Tenofovir. A web search found that the cost for a month’s supply of the antiviral drug averages just over $1,000. For some patients, that cost may be prohibitive. The cost is an issue of particular concern for developing countries, but it is also true that the price may be much lower for them than in the United States. Many pharmaceutical companies offer their drugs at steeply discounted rates in poorer countries to expand access to life-saving medicines. The release clearly says that 68 percent of women receiving the drug reduced their viral load while only 2 percent of the women in the control group had that success. It also says that the transmission of hepatitis B from mother to newborn dropped from 18 percent to 5 percent, an important clinical outcome. The release includes a discussion of harms. It states that “tenofovir was well tolerated; only one participant treated with tenofovir voluntarily withdrew from the study due to nausea.”  It also says that researchers “found no significant differences between the tenofovir-treated group and the control group with regard to fetal development and infant growth.”  Lastly, it calls for longer term, observational studies to confirm the safety of fetal exposure to tenofovir treatment. The release provides a good overview of the randomized, placebo-controlled trial which was undertaken to gauge the efficacy of the drug in both reducing the viral load of hepatitis-B-positive mothers and reducing the rate of transmission of the disease from mother to newborn. It offers solid, numerical evidence of both outcomes. It describes the number of patients (200 pregnant women), defined what constituted a “high” viral load, and described the approximate length of treatment. It did omit a mention of whether the trial was blinded. This release does not commit disease mongering. The release notes that the research is funded by Gilead Sciences. It should also have mentioned that a corresponding author disclosed speaking and advising fees from Gilead, according to the published study. The release is comparing the use of an antiviral drug given to pregnant women versus the normal procedure of giving both a vaccine and immune globulin. The release doesn’t mention that tenofovir (marketed as Viread), the drug being tested, is already an FDA approved drug so many readers may not know that it’s available. It was approved by the FDA in 2001 for HIV and in 2008 for chronic hepatitis B. The release just barely implies novelty with this statement which suggests a change in treating infected women who are pregnant: “Based on the findings, the investigators recommend that women be tested for HBV viral load at week 28 of pregnancy. Those with a high viral load should receive tenofovir treatment starting at gestational week 30 until delivery to reduce the risk of transmission to their infants.” While the drug itself isn’t novel, positive outcomes from a controlled trial on pregnant women carrying the virus does seem to introduce a new treatment approach. This release does not use any unjustifiable language.


Output: Antiviral Treatment During Pregnancy Reduces Mother-to-Child Transmission of Hepatitis B